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To fulfill the need for a simple and rapid diagnostic test for human brucellosis, we used the immunochro-
matographic lateral flow assay format to develop two assays, one for the detection of Brucella-specific immu-
noglobulin M (IgM) antibodies and one for the detection of Brucella-specific IgG antibodies. The diagnostic
values of these tests were examined. The tests are shown to detect acute, persistent, and relapsing disease and
can be used to monitor treatment. The sensitivity of Brucella IgM and IgG flow assays calculated for the
combined assay results is 96%, and specificity amounts to 99%. The flow assay requires neither specialized
training nor equipment, the assay is very easy to perform and to read, and the components are stable without
a requirement for refrigeration and well standardized. Together these characteristics indicate that the Brucella
IgM and IgG flow assays are ideal for use in clinical settings in rural and suburban areas in which brucellosis
is endemic.
Brucellosis is a multisystem disease showing great variability,
and the clinical picture can be misleading (12, 27). A proper
and prompt diagnosis is important, as the treatment of brucel-
losis is complicated, requiring specific antibiotics and, partic-
ularly in persistent disease, prolonged medication (24).
Culture provides definite proof of brucellosis but may not
provide a positive result for all patients (5, 9, 17). Brucella
bacteria are relatively slow growing, and the culture result may
not become available for several days or weeks (25). In partic-
ular for patients with chronic disease, the sensitivity of culture
can be low. Therefore, serological testing often is used for the
confirmation of brucellosis (26). Almost all serological tests
have been applied in the diagnosis of human brucellosis. The
most commonly used test is the serum agglutination test (SAT)
or Wright’s test (23). The anti-human globulin test (Coombs)
(19), the complement fixation test (14), and the enzyme-linked
immunosorbent assay (ELISA) (4, 15, 18, 20) also are used. A
laboratory that is capable of performing these slow and rela-
tively complicated assays may not be available in many places.
Under such conditions, the Rose Bengal test (RB) may be used
not only as a simple screening test but also as a confirmatory
test (10, 11).
In human brucellosis, specific immunoglobulin M (IgM) an-
tibodies usually develop early in the infection and remain
present for several weeks to months (4, 21). Specific IgG an-
tibodies tend to develop somewhat later but may remain
present, albeit at low levels, for months to years also after the
patient has recovered. IgG but not IgM antibodies usually are
present in recurrent infections. Specific agglutinating antibod-
ies are detected by RB and SAT. Coombs, SAT in the presence
of reducing agent, and more recently ELISA have been used
for the detection of specific IgG antibodies. Coombs and IgG
ELISA are particular useful when diagnosing patients with a
chronic infection and to monitor relapse. Detection of specific
IgM antibodies in ELISA is useful in diagnosing patients with
acute illness, given the fact that the IgM antibody response
tends to develop somewhat earlier than the IgG response. IgM
detection also is used to discriminate between acute and
chronic diseases, and for this SAT has been used as well (2, 16,
22). A significant reduction in titer in this assay when per-
formed in the presence of reducing agent indicates the pres-
ence of specific IgM antibodies.
To address the need for a simple and rapid diagnostic test,
we have applied the immunochromatographic lateral flow as-
say format to develop two assays, one for the detection of
Brucella-specific IgM and one for Brucella-specific IgG anti-
bodies.
The lateral flow assay is a simplified version of ELISA (Fig.
1). The assay consists of a nitrocellulose detection strip flanked
at one end by a reagent pad and at the other end by an
absorption pad. A sample application pad flanks the reagent
pad in turn. The composite strip is contained in a plastic assay
device. The detection strip contains Brucella lipopolysaccha-
ride (LPS) as a Brucella-specific capture probe as well as a
reagent control applied in distinct lines. The reagent pad con-
tains dried and stabilized detection reagent consisting of a
colloidal gold immune conjugate. Colloidal gold-conjugated
anti-human IgM was used as detection reagent in the IgM flow
assay, and colloidal gold-conjugated anti-human IgG was used
as detection reagent in the IgG flow assay. LPS was prepared
from a solid 3-day-old culture of Brucella abortus strain 1119-3
grown on Brucella agar in 250-ml culture flasks. Cells were
harvested in 50 ml of 0.9% NaCl per flask and inactivated by
the addition of 250 l of phenol and left for 2 days at 37°C and
4 days at 4°C (1). The inactivated cell suspension was centri-
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fuged for 30 min at 4,750  g, and the pellet was suspended in
25 ml of H2O and autoclaved for 30 min at 121°C. The mixture
was cleared by centrifugation for 30 min at 4,750  g, and LPS
was precipitated by the addition of 75 ml of ice-cold 96%
ethanol to the supernatant, incubated for 24 h at 4°C, and
centrifuged at 2,325 g for 15 min. Finally, the precipitate was
dissolved in 5 ml of H2O. Before use, the concentration was
adjusted by freeze-drying. Four-times-concentrated LPS was
used as a capture probe in the IgM flow assay, and two-times-
concentrated LPS was used as a capture probe in the IgG flow
assay. The LPS capture probe was applied to the detection
strip in a 2-mm-wide line by using a BioDot Quanti-2000 Biojet
apparatus. Human IgM was applied in a second line to func-
tion as a reagent control in the IgM flow assay, and human IgG
was applied in a second line to function as a reagent control in
the IgG flow assay. The colloidal gold immunoconjugate de-
tection reagents were prepared by Organon Teknika (Dublin,
Ireland) by conjugation of affinity-purified polyclonal human
IgM and IgG antibodies to 40-nm-diameter colloidal gold par-
ticles. The detection reagents were applied to the conjugate
pad by using a BioDot Airjet Quanti 2000 apparatus. Strip tests
were assembled by mounting the sample application pad, re-
agent pad, detection strip, and absorption pad onto a rigid
support and placing the strips in a plastic assay device with a
round sample well positioned above the sample pad and a
square detection and control window above the detection strip.
Finally, tests were sealed in a moisture-resistant protective foil
containing a bag with desiccant. The antigen preparation
method, the amount and concentration of LPS capture probe,
and the amount of detection reagent were optimized in a
step-by-step procedure using a panel of well-defined positive
and negative control sera. The running fluid consisted of phos-
phate-buffered saline, pH 7.6, containing 1.67% bovine serum
albumin and 3% Tween 20. Organon Teknika Ltd. manufac-
tured the flow assays used for evaluation.
The flow assay is simply performed by the addition of 5 l of
serum directly onto the sample application pad in the sample
well of the plastic assay device. Following the addition of some
test liquid, the result is read 10 to 15 min later by visual
inspection for staining of the antigen and control lines in the
test window of the device. The control line should stain in all
cases. The assay is scored negative when no staining of the
antigen line is observed and positive when a distinct staining of
the antigen line is observed. The antigen line may stain at
different intensities, and a positive result was subjectively rated
1 when staining was weak, 2 when staining was moderate,
3 when staining was strong, and 4 when staining was very
strong. Undetermined staining represented by very weak
FIG. 1. The Brucella IgM and IgG flow assays: physical presenta-
tion, components and method. The Brucella IgM and IgG flow assays
(A) consist of a plastic assay device (left) containing a composite assay
strip (right). The plastic assay device has a round sample application
pad (a) and a square test and control window (b). The assay strip
consists of a sample application pad (c), a conjugate pad (d) containing
dried detection reagent, a detection strip (e) with distinct test and
control lines, and an absorption pad (f). The assay procedure and test
result are presented in panel B. The test result of a serum sample (SAT
titer, 1:1,280; SAT-DTT, 1:40; Coombs, 1:1,280) giving a negative
result in the IgG flow assay and a strong positive result in the IgM flow
assay is presented.
TABLE 1. Results of Brucella IgM and IgG flow assays for different groups of sera and comparison with SAT, DTT-SAT, and Coombs
Serum group (no. of samples)
No. (%) of sera testing positive by indicated assay
SAT,
1:320
SAT,
1:160
SAT-DTT,
1:160
SAT-DTT,
1:80
SAT-DTT,
4-fold
reduction in
titer
Coombs,
1:320
IgM flow,
1
IgG flow,
1
IgM  IgG
flow, 1f
Initial samples from patients with clinical
suspicion of brucellosis
Albacete (54) 31 (57) 39 (72) 24 (44) 31 (57) 25 (46) 53 (98) 28 (52) 33 (61) 41 (76)
Malaga (81) 43a (57) 57a (76) 45b (62) 53b (73) 20 (27)b 68 (94)d 29 (36) 54 (67) 67 (87)
Pamplona (70) 52c (78) 58c (87) 53c (79) 49c (79) 30 (45)c 66 (99)c 47 (67) 50 (71) 65 (93)
Total (205) 127 (65) 154 (79) 122 (63) 133 (69) 75 (38) 187 (97) 104 (51) 137 (67) 173 (84)
Rev-1 contacts (10) 0 (0) 0 (0) NTe NT 0 (0) 6 (60) 0 (0) 4 (40) 4 (40)
Patients with fever from an area of nonendemicity
for brucellosis (79)
NT NT NT NT NT NT 1 (1) 1 (1) 1 (1)
Cases with illnesses other than brucellosis (197) NT NT NT NT NT NT 2 (1) 1 (1) 2 (1)
a Six sera were not tested.
b Eight sera were not tested.
c Three sera were not tested.
d Nine sera were not tested.
e NT, not tested.
f Positive (1) test result in at least one of the two flow assays.
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(/) staining was considered negative. The results of exposed
tests are stable after drying, but drying results in a slight loss of
staining intensity. The assay is based on the binding of specific
antibodies present in the clinical specimen to LPS antigen and
staining of the bound antibodies by a colloidal gold-labeled
antibody conjugate. By using two different conjugates, one for
the detection of IgM antibodies and one for IgG antibodies,
two complementary tests for the serodiagnosis of acute and
persistent human brucellosis were developed.
The results of the Brucella IgM and IgG flow assays were
compared with results by SAT (23), SAT performed in the
presence of dithiothreitol (SAT-DTT) (3), and Coombs (7) for
the initial serum samples collected from 205 patients who had
been referred for laboratory testing to different laboratories in
Spain because of clinical suspicion of brucellosis (Table 1).
Patients had been referred to the Infectious Diseases Unit of
the General Hospital of Albacete in Albacete (n  54 sera),
the Laboratory for Microbiology of the Hospital Virgen de la
Victoria in Malaga (n  81), and the Department of Microbi-
ology of the University of Navarra in Pamplona (n  70). The
IgM flow assay tested positive in 51% of the sera, and the IgG
flow assay tested positive in 67% of the sera. A total of 173
(84%) sera tested positive in at least one of the two flow assays.
This number was significantly higher (P  0.004) than the
number of sera that tested positive by SAT (79%) at a cutoff
value of 1:160 but was lower than the number testing positive
by Coombs (97%). SAT-DTT indicated the presence of spe-
cific IgM antibodies in 38% of the sera.
The IgM and IgG flow assays tested positive for just 1 of 79
patients from a control group of hospitalized patients with
fever from an area where the disease is not endemic. A positive
result also was obtained for 1 of 31 rheuma factor-positive sera,
and for the serum of one of 34 patients with malaria. The
rheuma factor-positive serum that tested positive was from a
patient from an area where brucellosis is endemic. The flow
assays scored negative for samples from patients with various
diseases other than brucellosis, including patients with tuber-
culosis (n  24), human immunodeficiency virus-positive pa-
tients (n  19), and patients with typhoid fever (n  17),
leptospirosis (n  16), hepatitis B (n  16), hepatitis C (n 
10), and arthritis (n 30). Reactivity of the IgG flow assay was
noted to be present in the sera from four veterinarians who had
been involved in the vaccination of animals with the Rev-1
vaccine. Six other sera from Rev-1 contacts tested negative.
The IgM flow assay was negative for all 10 sera. The Coombs
test gave positive resutls for the sera from six Rev-1 contacts,
two of which also tested positive in the IgG flow assay. The
titers observed in SAT for the control sera were all below the
cutoff used for diagnosis.
Sensitivity and specificity are two important characteristics
of a diagnostic test. The clinical symptoms of brucellosis may
closely resemble those of other illnesses, and in areas of en-
demicity SAT and Coombs may give positive results in non-
brucellosis patients due to residual antibodies from previous
exposure. The sensitivity of the flow assays thus cannot be
calculated based on the results obtained for the samples from
the patients with clinical suspicion of brucellosis and confirmed
by serological testing in SAT and Coombs. The sensitivity of
the IgM and IgG flow assays therefore was calculated based on
the results for 89 patients who were confirmed by culture (n 
73 cases) and or radial immunodiffusion test (RID) (n  49)
(Table 2). Culture provides definite proof of brucellosis, and
RID using native hapten, a homopolymer of N-formylperox-
amine presenting together with LPS on the surface of the
Brucella organisms, is highly specific (13). The sensitivities of
the IgM flow assay and the IgG flow assay were calculated to
be 67 and 71%, respectively. The combined results gave a
sensitivity of 96%, which is significantly higher (P  0.002)
than the sensitivity of 78% calculated for SAT for the same
group of sera at the diagnostic threshold titer of 1:320 (21).
The sensitivity of SAT at a cutoff value of 1:160, however,
was similar to that of the flow assays (P 0.05). The sensitivity
of Coombs at a cutoff value of 1:320 was 100% for this group
of confirmed patients. The specificity of the flow assay was
calculated to be 99% (95% confidence interval [CI]; range, 97
to 100), based on the results of the control groups of hospital-
TABLE 2. Sensitivity of Brucella IgM and IgG flow assays for initial
serum samples from patients with confirmed brucellosis and
comparison with other serological tests
Assay No. of positive samples(n  89)
% Sensitivity
(95% CI)
SAT, 1:320 69 78 (67–85)
SAT, 1:160 77 88 (78–93)
SAT-DTT, 1:160 55 62 (51–72)
SAT-DTT, 1:80 64 70 (61–81)
Coombs, 1:320 89 100 (95–100)
IgM flow 60 67 (57–77)
IgG flow 70 71 (61–79)
IgM  IgG flow 85 96 (88–99)
TABLE 3. Staining intensity of Brucella IgM and IgG lateral flow assays for serum samples collected at the time of first diagnosis
Assay and patient group
No. of serum samples with the indicated staining intensity
Negative / 1 2 3 4
Brucella IgM flow assay
Confirmed case patients 29 14 17 20 9
Unconfirmed patients with clinical suspicion of brucellosis 55 18 17 12 14 1
Controlsa 271 3 1 1
Brucella IgG flow assay
Confirmed case patients 16 3 24 27 13 6
Unconfirmed patients with clinical suspicion of brucellosis 34 15 37 19 5 6
Controls 273 1 2
a Patients with fever and patients with illnesses other than brucellosis.
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ized patients with fever and patients with illnesses other than
brucellosis. In this group of 276 sera, all but three tested
negative. The weak (1) reactivity of the IgG flow assay with
some of the sera from Rev-I contacts, however, indicates that
the specificity could be somewhat lower in specific risk groups.
Results of the flow assay are easy to read (Table 3). A
moderate (2) to very strong (4) staining in either or both of
the flow assays was observed for 88% (75 of 85) of the initial
sera from the confirmed brucellosis patients with a positive
result. For the other 10 positive patients a 1 staining was
recorded as the strongest test result. In the control groups a
clear negative result was obtained for 270 (97.8%) sera. The
sera of three patients tested positive, and the sera of three
other patients gave an undetermined (/) result in the IgM
flow assay. The correlation of the SAT titer with the reactivity
in the flow assays for the sera from the confirmed patients
shows that the results of the flow assays closely parallel those
of the agglutination test (Table 4). The five sera that had a
SAT titer of 1:40 and a moderate to very strong positive
result in the IgG flow assay all had high titers, ranging from
1:2,560 to 1:81,920 with Coombs.
Of the 89 patients with confirmed brucellosis, 15 tested pos-
itive in the IgM flow assay and were negative in the IgG flow
assay, 44 tested positive in both flow assays, 26 tested positive
in the IgG flow assay only, and 4 tested negative. A 4-fold
reduction in SAT titer in the presence of DTT was observed in
the serum samples from 12 of the confirmed patients with a
positive result in the IgM flow assay and a negative result in the
IgG flow assay. The Coombs titers (median titer, 1:1,280) were
relatively low for these patients. Patients with a positive result
in both flow assays had high Coombs titers (median titer,
1:10,240). Agglutination in SAT was DTT insensitive for 22
(50%) of these patients. The median Coombs titer for the sera
from these 22 patients was 1:20,480, compared with 1:5,120 for
the patients with a DTT-sensitive agglutination in SAT, sug-
gesting that the high levels of specific IgG antibody in these
patients masked the detection of specific IgM antibodies in
SAT-DTT. The detection of specific IgM antibodies in the IgM
flow assay apparently was not affected by the presence of these
high specific IgG antibody levels. Most of the 26 patients with
a positive result in the IgG flow and a negative result in the
IgM flow assay had relatively high Coombs titers (median titer,
1:10,240), and only 7 showed a reduction in SAT titer in the
presence of DTT. These results suggest that the flow assays
provide a more accurate tool for the discrimination between
specific IgM and IgG antibodies than the agglutination test.
The initial sample from four patients with confirmed brucel-
losis scored negative in both flow assays. SAT showed low,
insignificant titers (1:80) for the sera of two of these four
patients and tested positive for the two other patients. Coombs
was positive in all four patients. One of these four patients was
diagnosed with a small hepatic abscess years after he had been
treated for brucellosis. Brucella melitensis was isolated from the
abscess. Coombs gave a titer of 1:640, but the IgG in the sera
did not agglutinate in SAT. IgA purified from the serum
showed agglutinating activity that was sensitive for DTT. The
second patient presented an acute case with a blood culture
positive for B. melitensis. Only Coombs tested positive (1:640)
for this patient. The third patient also was culture positive, and
the serum of this patient reacted in SAT (1:320) and Coombs
(1:2,560). The fourth patient was culture negative with a serum
that agglutinated in SAT (1:1,280), was DTT sensitive, and
reacted weakly in Coombs (1:1,280).
The duration of illness at the time of diagnosis was recorded
for 36 patients with confirmed brucellosis (Table 5). Of these
patients, 23 had acute illness and 13 suffered from persistent
disease. Of the serum samples from acute-phase patients, 2
samples tested negative in both tests, 4 tested positive in the
IgM assay and negative in the IgG flow assay, 10 tested positive
in both tests, and 7 tested positive only in the IgG flow assay.
Of the sera from the patients with persistent disease, one
tested negative in both tests, two reacted only in the IgM flow
assay, two tested positive in both tests, and eight reacted only
in the IgG flow assay. The sensitivity of the flow assays was
91% for the patients with acute illness and 92% for the patients
with persistent disease. The sensitivity of the flow assays was
higher than that of SAT but lower than that of Coombs for
each of the two groups.
Culture and RID were negative (n  46) or not performed
(n  70) for 116 patients with an unconfirmed clinical diagno-
sis of brucellosis. SAT with a titer of 1:320 (referred to
hereafter as SAT, 1:320), SAT, 1:160, SAT-DTT, 1:160,
SAT-DTT, 1:80, Coombs, and the IgM and IgG flow assays
TABLE 4. Correlation of staining intensity of Brucella IgM and
IgG flow assays with SAT titer for patients with
confirmed brucellosis
Staining
intensity
in flow
assaya
No. of sera with indicated SAT titer
1:20 1:40 1:80 1:160 1:320 1:640 1:1,280 1:2,560 1:5,120 1:10,240
4 1 1 1 3 3 4 2
3 1 3 2 3 4 9 6 2
2 1 2 8 10 9 2 3 1
1 2 1 2 2 2
Negative 2 1 1
a The staining intensity for either the IgM or IgG flow assay is given, whichever
was highest.
TABLE 5. Presence of specific IgM and IgG antibodies in patients with acute and persistent brucellosis
Stage of illnessa
No. of patients with positive result (% positive, 95% CI) in the indicated assay
SAT, 1:320 SAT, 1:160 SAT-DTT,
1:160
SAT-DTT,
1:80
SAT-DTT,
4-fold titer
reduction
Coombs, 1:320 IgM flow,
1 IgG flow, 1
IgM 
IgG flow, 1b
Acute (n  23) 16 (70, 47–86) 20 (87, 65–97) 11 (48, 27–69) 13 (57, 35–76) 15 (65, 43–83) 23 (100, 82–100) 14 (61, 39–80) 17 (74, 51–89) 21 (91, 71–99)
Persistent (n  13) 7 (54, 26–80) 9 (69, 39–90) 3 (23, 6–54) 5 (39, 15–68) 5 (39, 15–68) 13 (100, 72–100) 4 (31, 10–61) 10 (77, 46–94) 12 (92, 62–100)
a Acute, 3 months of illness at diagnosis; persistent, 3 months of illness at diagnosis.
b Positive (1) test result in at least one of the two flow assays.
1144 NOTES CLIN. DIAGN. LAB. IMMUNOL.
tested positive in 54, 72, 52, 66, 93, 38, and 58%, respectively,
of the initial sera of this group of patients. SAT-DTT indicated
the presence of specific IgM antibodies in 29% of the sera. The
IgM and IgG flow assays combined gave a positive result for a
total of 88 (76%) patients, and of these, 57 (64%) showed a
moderate to very strong staining (Table 3). The other 31 pos-
itive sera gave a 1 staining. For this heterogeneous group of
patients also the results of the flow assays closely paralleled
those of SAT, and given the demonstrated high sensitivity and
specificity, the results of the flow assays confirmed the diagno-
sis in a high percentage of the cases. A number of patients that
were considered negative gave an indeterminate reactivity in
the flow assay. Such cases would require further investigation
by testing follow-up sera or laboratory testing in other tests.
The number of positive results in the IgM and IgG flow
assays decreased during the follow-up of treated patients (Ta-
ble 6). The number of positive results in the IgM flow assay
decreased from 62 to 31% in the first 3 months after treatment
and decreased further, to around 20%, during the following 3
months. In the IgG flow assay the number of patients with a
positive result slightly increased during the first 2 months of
treatment and gradually decreased to 38% for samples col-
lected after more than 6 months of follow-up. The number of
SAT-positive patients also rapidly declined during follow-up.
Coombs titers remained high during follow-up, with some re-
duction in the number of positive patients observed after 6
months. The decrease in the number of patients with a positive
result in the flow assays coincided with a reduction in the
staining intensity of the antigen band (Table 7). The tests thus
may be used to monitor the effects of treatment.
For two relapsing patients, the reactivity observed in the IgG
flow assay was strongly increased for the samples collected
during and after relapse over that observed for the sample
collected at first diagnosis. For one of these two patients who
became blood culture positive 1 year after treatment, the initial
serum sample collected at first diagnosis tested 2 in the IgM
flow assay and 1 in the IgG flow assay and the serum col-
lected after relapse tested indeterminate in the IgM flow assay
and 3 in the IgG flow assay. These results were in agreement
with those of SAT, SAT-DTT, and Coombs.
In areas of endemicity the diagnosis of brucellosis may be
hampered by lack of expertise and laboratory facilities to per-
form the currently available diagnostic tests. The Brucella IgM
and IgG flow assays fulfill this need. The sensitivity and spec-
ificity of this assay system for samples collected at the time of
first diagnosis are high, 96 and 99%, respectively, allowing an
accurate and early diagnosis. The sensitivity is high for acute as
well as chronic cases. The assay is also user-friendly; it is very
simple to perform without the need for specific equipment,
training, or electricity. Importantly, the assay gives a very clear
result and is very easy to read by visual inspection for staining
of a line in the test zone of the assay device. Moreover, the
assay components are highly stable and devices can be stored
for a prolonged time without the need for refrigeration.
The high sensitivity and specificity of the flow assays allow
their use as a confirmatory test in all cases in which symptoms
and signs lead to suspect the presence of brucellosis. In clinical
practice the flow assays may be used as a confirmatory test in
combination with RB as a screening assay. A positive result by
RB together with a positive test in either of the two flow assays
should be considered consistent with brucellosis. It may be
noted, though, that the results of RB may vary depending on
the quality of the particular antigen batch used (8) and that
culture remains the preferred method because it provides def-
inite proof.
When using the flow assays, the Brucella IgM and the Bru-
TABLE 6. Brucella IgM and IgG flow assay results and comparison with standard serological assays during follow-up of treated patients
Period (mo) (n)a
% Positive (95% CI) in the indicated assay
IgM flow, 1 IgG flow, 1 SAT, 1:320 SAT, 1:160 SAT-DTT, 4-foldtiter reduction Coombs, 1:320
Initial sample (26) 62 (41–79) 69 (48–85) 54 (34–73) 73 (52–88) 54 (34–73) 100 (84–100)
0–1 (16) 75 (44–87) 81 (50–92) 44 (21–69) 81 (50–92) 68 (39–85) 88 (62–98)
1–2 (23) 61 (39–80) 87 (61–94) 26 (11–49) 48 (27–69) 35 (17–57) 91 (71–99)
2–3 (16) 31 (12–59) 69 (42–88) 19 (5–46) 31 (12–89) 31 (12–59) 88 (58–96)
3–6 (18) 22 (7–48) 61 (36–82) 6 (0–29) 22 (7–48) 18 (4–42) 83 (58–96)
6 (21) 19 (6–43) 38 (19–61) 0 (0–20) 10 (2–32) 19 (6–43) 57 (34–77)
a n, number of samples.
TABLE 7. Decreased staining intensity of Brucella IgM and IgG lateral flow assays during follow-up of treated patients
Period (mo) (n)a
No. of serum samples with the indicated staining intensity in:
Brucella IgM flow assay Brucella IgG flow assay
Negative / 1 2 3 4 Negative / 1 2 3 4
Initial sample (26) 9 1 1 4 9 2 5 3 7 6 2 3
0–1 (16) 4 1 3 3 5 1 2 2 5 4 4
1–2 (23) 9 1 3 9 1 3 1 9 7 2 1
2–3 (16) 6 5 3 2 2 3 5 4 2
3–6 (18) 9 5 4 5 2 4 7
6 (21) 15 3 3 7 6 7 1
a n, number of samples.
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cella IgG flow assays should be used as complementary tests.
Only some of the cases with suspected acute brucellosis gave a
positive result in the IgM flow assay. Others gave a positive
result in the IgG flow assay instead. Among the cases with
suspected persistent brucellosis, some reacted in the IgG flow
assay and some reacted in the IgM flow assay. The use of the
flow assays will thus require the simultaneous or sequential use
of the two tests, and this will allow the confirmation of a high
percentage of acute cases with brucellosis as well as those with
a longer duration of illness.
The lateral flow assay may also be used in the follow-up of
patients undergoing treatment and to study relapse. A rapid
decline in response in the lateral flow assay was observed for
patients undergoing treatment. For patients showing relapse, a
strong response in the IgG flow assay was noticed in the sera
collected at the time of relapse. However, this observation
requires investigation of a larger number of patients in order to
be confirmed but is consistent with the notion that during
relapse specific IgG but not IgM antibodies usually are formed
(6).
In conclusion, the availability of a rapid and simple assay
system for human brucellosis such as the Brucella IgM and IgG
flow assays is important, as it takes testing out of the hands of
well-equipped laboratories and puts it in the hands of physi-
cians who can use it in health centers and district hospitals and
also in private practice. The test is especially suited for use in
suburban and rural areas in countries where the disease is
endemic.
We thank Sophie Gill for dedicated technical advice and manufac-
turing of development and evaluation lots of flow assays.
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